


RealRate

PHARMACEUTICAL 2021

## CORCEPT THERAPEUTICS INC Rank 5 of 409









PHARMACEUTICAL 2021



CORCEPT THERAPEUTICS INC Rank 5 of 409



The relative strengths and weaknesses of CORCEPT THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CORCEPT THERAPEUTICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 527% points. The greatest weakness of CORCEPT THERAPEUTICS INC is the variable Other Assets, reducing the Economic Capital Ratio by 3.9% points.

The company's Economic Capital Ratio, given in the ranking table, is 325%, being 679% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	478,501
Cost of Goods Sold	5,582
Intangible Assets	0
Liabilities, Current	47,494
Liabilities, Non-Current	501
Other Assets	91,555
Other Compr. Net Income	154
Other Expenses	25,591
Other Liabilities	398
Other Net Income	3,400
Property and Equipment	1,675
Research and Development	114,764
Revenues	353,874
Selling, General and Administrative Expense	105,326

Output Variable	Value in 1000 USD
Assets	571,731
Liabilities	48,393
Expenses	251,263
Stockholders Equity	523,338
Net Income	106,011
Comprehensive Net Income	106,088
Economic Capital Ratio	325%

